Clinical Trial Update: Study Of The Safety And Efficacy Of Conversion From A CNI To Sirolimus In Renally-Impaired Heart Transplant Recipients [Phase 4]

View source ↗

Summary

Phase 4 study assessing safety and efficacy of converting from a calcineurin inhibitor to sirolimus in renally impaired heart transplant recipients; results com…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft Rejection
• Heart Transplantation
• Kidney Failure

Drugs mentioned

• Sirolimus (Sirolimus)

Snippet

Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer | Conditions: Graft Rejection, Kidney Failure | Phase 4 | Status: COMPLETED | Results posted: 2011-05-23